<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20050920144436+02'00'</creation_date><modification_date>D:20060322183715+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_dec_3.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 19-ix-2005 c(2005)3609 
 not for publication</p></section><section><header>commission decision of 19-ix-2005 
 amending the marketing authorisation for &quot;ariclaim - duloxetine hydrochloride&quot;, a 
 medicinal product for human use, granted by decision c(2004)3160</header><p>only the german text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 19-ix-2005 
 amending the marketing authorisation for &quot;ariclaim - duloxetine hydrochloride&quot;, a 
 medicinal product for human use, granted by decision c(2004)3160 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorisation and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the first subparagraph of article 6(10) thereof, 
 having regard to the application submitted by boehringer ingelheim international gmbh 
 on 30 may 2005 under article 6(1) of commission regulation (ec) no 1085/2003, 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 27 july 2005, 
 whereas: 
 (1)</p><p>an examination of the major variation type ii to the terms of the marketing 
 authorisation for the medicinal product &quot;ariclaim - duloxetine hydrochloride&quot;, 
 which is entered in the community register of medicinal products under no(s) 
 eu/1/04/283/001-007 and the placing on the market of which was authorised by 
 decision c(2004)3160 of 11 august 2004, has shown that the product remains in 
 compliance with the requirements set out in directive 2001/83/ec of the</p><p>
 1 oj l 214, 24.8.1993, p. 1. regulation as last amended by [regulation (ec) no 1647/2003 (oj l 245, 29.9.2003, p. 19)]. 
 2 oj l 159, 27.6.2003, p. 24.</p></section><section><header>en  
   en</header><p>european parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use
 3. (2)</p><p>it is therefore appropriate to accept the application in respect of a major variation 
 to the terms of the marketing authorisation and to amend decision c(2004)3160 
 accordingly. 
 (3)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c (2004)3160 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)3160 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex iii b is replaced by the text set out in annex iii b to this decision. 
 article 2 this decision is addressed to boehringer ingelheim international gmbh, binger strasse 173, d-55216 ingelheim am rhein, deutschland. 
 done at brussels, 19-ix-2005 
 for the commission g√ºnter verheugen 
 member of the commission</p><p>3 oj l 311, 28.11.2001, p. 67. directive as last amended by [directive 2004/27/ec (oj l 136, 30.4.2004, p.34)].</p></section></body></xml>